益盛药业(002566) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was CNY 200,410,031.97, a decrease of 18.10% compared to CNY 244,687,559.79 in the same period last year[9] - Net profit attributable to shareholders was CNY 21,483,641.33, an increase of 27.34% from CNY 16,871,558.99 year-on-year[9] - Basic earnings per share rose to CNY 0.0649, reflecting a growth of 27.25% compared to CNY 0.0510 in the same quarter last year[9] - The company's operating profit for Q1 2020 was CNY 31,513,381.89, an increase of 35% compared to CNY 23,355,685.80 in the same period last year[41] - Total profit for Q1 2020 reached CNY 29,813,960.90, up from CNY 22,831,521.01, reflecting a growth of 30% year-over-year[41] - The company reported a total comprehensive income of CNY 25,202,056.45 for Q1 2020, compared to CNY 19,746,399.38 in the same period last year, an increase of 28%[42] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 56.00% to CNY 31,724,684.07 from CNY 72,102,073.45 in the previous year[9] - Cash and cash equivalents increased by 40.85% to ¥88,753,739.80 from ¥63,014,615.13 due to higher net cash inflows from operating activities[19] - The company reported a significant decrease in cash received from operating activities, with a drop of 65.62% in other operating cash receipts to ¥7,445,649.18 from ¥21,655,390.40[19] - The net cash flow from operating activities was 31,724,684.07 CNY, a decrease of 56.1% compared to 72,102,073.45 CNY in the previous period[49] - The company incurred cash outflows of 204,418,446.85 CNY from operating activities, slightly down from 209,259,082.96 CNY in the previous period[49] - Cash inflows from financing activities were 110,000,000.00 CNY, compared to 200,000,000.00 CNY in the previous period, indicating a 45% decrease[50] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,503,032,462.36, a slight increase of 0.26% from CNY 2,496,513,671.23 at the end of the previous year[9] - Total liabilities decreased to CNY 419,978,806.85 from CNY 438,662,072.17, a decline of about 4.5%[34] - Total assets amounted to 2,505,218,983.50, with current assets at 1,729,611,557.12 and non-current assets at 775,607,426.38[58] - Total liabilities reached 604,212,756.22, with current liabilities at 569,177,496.77 and non-current liabilities at 35,035,259.45[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,737[13] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[13] - The net assets attributable to shareholders increased by 1.11% to CNY 1,953,689,073.16 from CNY 1,932,205,431.83 at the end of the previous year[9] - Total equity attributable to shareholders increased to CNY 1,953,689,073.16 from CNY 1,932,205,431.83, reflecting a growth of approximately 1.1%[34] Operating Costs and Expenses - Total operating costs for Q1 2020 were CNY 174,222,202.57, down from CNY 220,037,363.00 in the previous period[40] - The company reported a decrease in sales expenses to CNY 95,951,134.28 from CNY 125,561,248.13, a reduction of about 23.6%[40] - Research and development expenses increased to CNY 4,295,439.68 from CNY 3,451,674.58, representing an increase of approximately 24.5%[40] Government Subsidies - The company received government subsidies amounting to CNY 7,628,672.34 during the reporting period[10] - Other income surged by 393.79% to ¥7,741,091.20 from ¥1,567,689.64, primarily due to an increase in government subsidies received[19] Miscellaneous - The company has not undergone an audit for the first quarter report[60] - The company is implementing new revenue and lease standards starting in 2020, with no retrospective adjustments required[60] - The chairman of the company is Zhang Yisheng, indicating leadership continuity[61]